Chronic myelogenous leukemia stem cells: What’s new?
Posted by rob on April 29, 2010 under Uncategorized | 
Comments are off for this article
Chronic myelogenous leukemia stem cells: What’s new?
Curr Hematol Malig Rep. 2009 Apr;4(2):66-73
Authors: Copland M
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that arises in the hematopoietic stem cell compartment. CML is one of the best-understood malignancies, as it results from a single genetic mutation, the fusion oncogene BCR-ABL, which has been widely studied. Specific tyrosine kinase inhibitors have been developed to target BCR-ABL in CML, but these agents fail to eliminate the CML stem cell population and thus are unlikely to cure CML. This article reviews recent developments in the biology and treatment of CML, specifically focusing on CML stem cells. Significant progress continues to be made in our understanding of CML stem cell biology, which has wider implications within the cancer stem cell field. We are also beginning to see the identification of novel therapies that specifically target the CML stem cell. These are exciting times in the quest to cure CML.
PMID: 20425417 [PubMed - in process]